Towards early inclusion of children in tuberculosis drugs trials: a consensus statement
about
Delamanid expanded access novel treatment of drug resistant tuberculosisRecent Developments and Future Opportunities in the Treatment of Tuberculosis in ChildrenTuberculosis innovations mean little if they cannot save livesToward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel.Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.When to start paediatric testing of the adult HIV cure research agenda?Synthetic investigational new drugs for the treatment of tuberculosis.Childhood TB: can the End TB Strategy deliver?Adverse effects of oral second-line antituberculosis drugs in children.Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations.Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challengesChallenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children.Regulatory and Ethical Issues in Pediatric Clinical Research: Recommendations From a Panel Discussion.Challenges in childhood tuberculosis.Tuberculosis in Children
P2860
Q26775858-57C67800-0B7E-4675-AAE6-ACB7504E53F3Q28085210-66C2E3B9-6E59-4A6B-B1FD-90C77C25B257Q33627409-98139ED2-1615-40EC-BB06-6933F15FF4BCQ36635719-560FADF1-80F8-4992-B799-B91E5185CF53Q37339276-55C0728A-E3B4-43E7-B6EB-C4A8F06E6A42Q37339290-CC7F58A2-0453-499B-8966-C27BD4581E92Q37339294-27D1C363-EF59-4C0E-8E48-5B5E5316C588Q37627212-4AFFB134-14A4-4E8C-BF2D-9A5C340491A8Q38635790-1C83C634-9BC3-4B35-B9D5-7A78A6769759Q38736697-280833E2-9127-45D6-842D-035BD7CD5B9FQ38837774-5D55749E-EDE8-4442-9D63-16E3BB037E94Q38874266-CDEE39CB-A3EB-4457-99AC-9238A31B209DQ39010772-581B2083-0AD2-4A76-A656-304284956345Q42399097-EE045C49-E08A-4E8F-B4D1-F4B32A1B1ED9Q47244908-455BB05A-4248-4727-BB34-25891B07A2DCQ50437780-51302766-0460-4869-84B9-F10BD955788FQ50581921-5A623724-274B-4900-9E5C-BDD251EFAEBEQ56508001-A346BFAC-E8B1-4AAC-857A-4A1BCC74B7E7
P2860
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement
@ast
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement
@en
type
label
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement
@ast
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement
@en
prefLabel
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement
@ast
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement
@en
P2093
P2860
P50
P1476
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement
@en
P2093
Amina Ahmed
Anneke Hesseling
Ariel R Porcalla
Ben Marais
Carl Mendel
Carol Worrell
Cleotilde How
Clydette Powell
David F McNeeley
E Gloria Anyalechi
P2860
P304
P356
10.1016/S1473-3099(15)00007-9
P577
2015-05-06T00:00:00Z
2015-06-01T00:00:00Z